BACKGROUND: Hepatoblastoma is a rare childhood liver cancer with an obscure etiology, however it is potentially associated with selected pregnancy events and hepatoblastoma risk in offspring. METHODS: Adjusted unconditional logistic regression estimated odds ratios (OR) and corresponding 95% confidence intervals (CI) for self-reported pregnancy events and medication use in a sample of mothers of 383 childhood hepatoblastoma cases and 387 controls. RESULTS: Risk of hepatoblastoma was significantly associated with maternal first trimester weight gain (OR = 1.02; 95% CI 1.00, 1.04 per 1 lb increase and nearly significantly with maternal multivitamin use (OR = 0.73; 95% CI 0.51, 1.03). Hepatoblastoma was not associated with other maternal weight changes, maternal illness or medication use during pregnancy. CONCLUSION: We found little evidence that maternal illness or most medication use during pregnancy are associated with hepatoblastoma in offspring.
BACKGROUND:Hepatoblastoma is a rare childhood liver cancer with an obscure etiology, however it is potentially associated with selected pregnancy events and hepatoblastoma risk in offspring. METHODS: Adjusted unconditional logistic regression estimated odds ratios (OR) and corresponding 95% confidence intervals (CI) for self-reported pregnancy events and medication use in a sample of mothers of 383 childhood hepatoblastoma cases and 387 controls. RESULTS: Risk of hepatoblastoma was significantly associated with maternal first trimester weight gain (OR = 1.02; 95% CI 1.00, 1.04 per 1 lb increase and nearly significantly with maternal multivitamin use (OR = 0.73; 95% CI 0.51, 1.03). Hepatoblastoma was not associated with other maternal weight changes, maternal illness or medication use during pregnancy. CONCLUSION: We found little evidence that maternal illness or most medication use during pregnancy are associated with hepatoblastoma in offspring.
Authors: S de Fine Licht; L S Schmidt; N H Rod; K Schmiegelow; P M Lähteenmäki; P Kogner; C Träger; T Stokland; J Schüz Journal: Int J Cancer Date: 2012-01-03 Impact factor: 7.396
Authors: Colleen C McLaughlin; Mark S Baptiste; Maria J Schymura; Philip C Nasca; Michael S Zdeb Journal: Am J Epidemiol Date: 2006-03-01 Impact factor: 4.897
Authors: Lucie M Turcotte; Michael K Georgieff; Julie A Ross; James H Feusner; Gail E Tomlinson; Marcio H Malogolowkin; Mark D Krailo; Nicole Miller; Rachel Fonstad; Logan G Spector Journal: Pediatr Blood Cancer Date: 2014-07-15 Impact factor: 3.167
Authors: Kimberly J Johnson; Katherine S Williams; Julie A Ross; Mark D Krailo; Gail E Tomlinson; Marcio H Malogolowkin; James H Feusner; Logan G Spector Journal: Cancer Epidemiol Biomarkers Prev Date: 2013-08-15 Impact factor: 4.254
Authors: Rajkumar Venkatramani; Logan G Spector; Michael Georgieff; Gail Tomlinson; Mark Krailo; Marcio Malogolowkin; Wendy Kohlmann; Karen Curtin; Rachel K Fonstad; Joshua D Schiffman Journal: Am J Med Genet A Date: 2014-06-16 Impact factor: 2.802
Authors: Deborah A Bilder; Amanda V Bakian; Joseph Viskochil; Erin A S Clark; Elizabeth L Botts; Ken R Smith; Richard Pimentel; William M McMahon; Hilary Coon Journal: Pediatrics Date: 2013-10-28 Impact factor: 7.124
Authors: Zuelma A Contreras; Beate Ritz; Jasveer Virk; Myles Cockburn; Julia E Heck Journal: Cancer Causes Control Date: 2016-09-09 Impact factor: 2.532